EverHint Signal — EMA10 × EMA30 Crossover — November 21, 2025

What This Signal Is (Quick)

The EMA10 × EMA30 Crossover scanner looks for fresh shifts in momentum where the 10-day exponential moving average (EMA10) crosses the 30-day EMA (EMA30) on today’s close. A bullish “Buy” trigger fires when EMA10 crosses up through EMA30; a bearish “Sell” trigger fires when EMA10 crosses down through EMA30.

Because both are exponential averages, this setup reacts faster than classic EMA10 × SMA50 or SMA20 × SMA50 crossovers. That makes it better for short-to-medium swing windows (roughly 1–4 weeks) but also more prone to whipsaws in choppy markets.

As always on EverHint, this is an experimental scanner for idea generation and back-testing, not a ready-made trading system. Position sizing, timing, and risk management are on you.

How We Ranked Today (Reader Version)

For today’s report (signals dated 2025-11-21), the universe includes 56 tickers with either a fresh buy or sell crossover.

Ranking logic for this post:

• Buy-side signals
  • Sorted by RSI(14) ascending (lower RSI = more “oversold” within an emerging up-move).
  • Preference for liquid names via 20-day average dollar volume in the backend.
• Sell-side signals
  • Sorted by RSI(14) descending (higher RSI = more extended conditions as momentum rolls over).

Overlays applied on top of the raw crossover signal:

• Insider flows (last 90 days) – Net open-market insider buying vs selling, using only P (Purchase) and S (Sale) transactions. Grants, awards, exercises, and tax events are ignored.
• Earnings proximity – Days until the next earnings report, based on forward earnings calendars (BMO/AMC noted in the commentary where relevant).
• Liquidity and size – Market cap and average dollar volume used internally to down-weight illiquid names.

Tables below are for education and research only – a snapshot of how this experimental scanner sees the tape today, not trade recommendations.

📈 Buy-Side EMA10 × EMA30 Crossovers (Top 10 by RSI)

Field notes – Buy side

• AAL (American Airlines) – RSI in the mid-40s with a fresh bullish EMA10×EMA30 crossover as the stock tries to stabilize above its 200-day trend. No recent insider signal, but earnings are still ~2 months out, leaving room for a pre-earnings swing if the broader tape cooperates.
• Healthcare cluster (WST, RARE, ENSG, BIO, ALGN, BMRN) – A large chunk of today’s bullish crossovers are mid- to large-cap healthcare names. The group is coming off neutral RSI (50–58), so this looks more like continuation than deep-value mean reversion. ENSG shows modest net insider selling (~$0.2M), suggesting some trimming into strength but nothing extreme at today’s market cap.
• TNL (Travel + Leisure) – Consumer cyclicals are represented via TNL, with a solid up-trend and fresh crossover but notable net insider selling (~$6.4M) over the last 90 days. That doesn’t invalidate the technical signal, but it is a caution flag for traders who care about management’s behavior.
• ADPT (Adaptive Biotechnologies) – Small-cap healthcare with a higher-beta profile. Net insider selling around $1.5M and a still-elevated RSI in the mid-50s suggest this is more of a momentum continuation than an under-owned turnaround.

Recent headlines – Buy-side highlights

• AAL – American Airlines
  • Zacks compares Delta vs. American and currently leans toward DAL on guidance and balance-sheet strength, underscoring that AAL is still a more speculative leg of the airlines trade, even as it triggers a bullish crossover.
    • DAL vs. AAL: Which Airline Stock Looks More Promising Now?
  • MarketWatch notes a slowdown in Thanksgiving booking momentum, suggesting near-term revenue optics for U.S. airlines could be softer than earlier expectations.
    • People were booking their Thanksgiving flights at a fast clip. Here's why that ended.
• TNL – Travel + Leisure
  • Business Wire highlights RCI (under the Travel + Leisure umbrella) rolling out an upgraded cruise and travel program, a modest fundamental tailwind for member engagement and ancillary revenue.
    • RCI Rolls Out Upgraded Cruise Program for Members
  • Additional coverage on TNL focuses on timeshare and travel demand normalization, aligning with the idea of a steady, not explosive, recovery trade.
• ALGN & BMRN (Growth healthcare)
  • Recent articles on ALGN discuss expectations around upcoming earnings and procedure volumes, framing it as a sensitivity play on consumer discretionary health spend (orthodontics and cosmetic dentistry).
  • BMRN coverage centers on its rare-disease pipeline and regulatory milestones, consistent with a “story stock” profile where news flow can move the name quickly around earnings or trial readouts.
• RARE & ADPT (Smaller biotech)
  • Defense- and fund-flow–oriented coverage notes position changes by institutional holders in RARE and ADPT, reflecting ongoing portfolio re-balancing rather than a clean, one-directional accumulation story.

📉 Sell-Side EMA10 × EMA30 Crossovers (Top 10 by RSI)

Field notes – Sell side

• Precious metals (WPM, GFI) – Both Wheaton and Gold Fields show sell-side crossovers with neutral-to-slightly-elevated RSI. This fits a narrative where the recent run in gold-linked names is cooling, but not yet in full-blown trend reversal territory.
• SONY – Interestingly, SONY triggers a bearish EMA10×EMA30 crossover even as recent analyst commentary has turned more constructive. That tension between improving fundamentals and softening price trend is exactly the sort of setup many traders watch for failed breakdowns or false moves.
• Financials (MUFG, BK, FCFS) – Large-cap financials here show crossovers with mid-range RSI, hinting at fatigue rather than extremes. No notable insider buying; FCFS has modest net selling, which fits profit-taking after a strong multi-quarter move.
• PCG (Utilities) – A defensive utility name showing a sell-side crossover and mid-40s RSI can signal rotation out of defensives when risk appetite creeps back into small caps and beta names.
• Tech swing candidates (FN, NXT, CLBT) – Fabrinet (FN) and Nextpower (NXT) stand out: both show bearish crossovers plus meaningful net insider selling (~$5.5M and ~$1.0M respectively) within the last 90 days. For traders who use insider activity as a filter, these are higher-risk short or de-risk candidates rather than casual fades.

Recent headlines – Sell-side highlights

• SONY – Sony Group Corporation
  • Zacks recently upgraded SONY to a “Strong Buy”, pointing to improving earnings prospects. The fact that price has rolled into a sell-side crossover while fundamentals improve makes this a potential “buy the dip vs trend break” battleground.
    • Sony (SONY) Upgraded to Strong Buy
  • Income-oriented coverage emphasizes Sony’s dividend profile and shareholder-return strategy, which may limit downside for longer-term holders even if the short-term trend softens.
• BK – Bank of New York Mellon
  • Business Wire reports a shareholder investigation and potential fiduciary-duty claims against BK’s directors and officers – not an earnings event, but headline risk that can weigh on sentiment while the technical picture weakens.
    • Investor Alert re: BK Directors and Officers
• Healthcare/biotech on the sell sheet
  • Several growth names on the broader signal list (not all in the top-10 table) show cautious institutional positioning, with stake trims reported in fund filings rather than outright exits. That fits a risk-management rotation rather than a slammed-door exit from the sector.

Field Notes – How to Read These Metrics

• RSI(14) – A momentum oscillator on a 0–100 scale.
  • Below ~40: momentum has been under pressure recently.
  • 40–60: neutral “grind” zone.
  • Above ~60: sustained strength or overbought conditions.
• Insider Net (USD) – Net open-market buying minus selling over the last 90 days.
  • Large positive values can signal insiders stepping in.
  • Large negative values suggest management or major holders are taking chips off the table.
  • Small values (or “—”) are effectively noise.
• Days → Earnings – Calendar days until the next earnings release.
  • <7 days: event-risk zone; swings can reverse quickly on the print.
  • 7–30 days: earnings drift window.

30 days: less event-driven, more technically driven.

For swing traders, combining trend (EMA cross), momentum (RSI), behavioral flows (insiders), and event timing (earnings) can create a more robust watchlist than any one signal alone.

Vlad’s Take (EverHint)

Today’s market backdrop from the snapshot:

• Major indices – S&P 500 closed around +0.72%, Nasdaq +0.50%, and the Dow +0.95%, while the Russell 2000 small-cap index outperformed with a +2.72% surge.
• Volatility – The VIX slipped to roughly 23.4 (about -9.8% on the day): still elevated versus calm regimes, but clearly easing from prior stress levels.
• Crypto – Bitcoin and Ethereum both traded lower (about -1.6% and -2.2%, respectively), suggesting some de-risking in crypto even as equities leaned risk-on.
• Rates – The 10-year Treasury yield hovered near 4.07%, edging slightly down on the day, which helps growth and duration-sensitive names at the margin.

Net-net, this looks like a “cautiously risk-on” session: small caps ripping, volatility backing off, and rates not getting in the way. In that context:

• Buy-side EMA10 × EMA30 crossovers in healthcare and select cyclicals look more attractive, especially where insider selling is modest and earnings are not imminent. Names like WST, ALGN, and BMRN fit the “quality swing” bucket if the tape holds.
• Sell-side crossovers in precious metals and select financials may represent either tactical profit-taking or early warnings of deeper rotation. For systems traders, these are good candidates for tightening stops, partial profit locks, or hedges.
• The mixed picture in SONY (bullish analyst upgrades vs bearish crossover) is a good reminder that no single input wins alone. These signals are best used as research prompts, not binary “in or out” switches.

Given the VIX above 20, I’d still favor tiered entries, smaller position sizes, and clear stop levels, even when the signal looks clean.

This is not financial advice. Do your own due diligence.
See https://www.everhint.com/disclaimer/ and https://www.everhint.com/faqs/

Independent, data-driven signals.
No hype. No promotions. Just experimental market research from EverHint.